Company Overview
About Asimov
Asimov is a Boston-based biotechnology and computational biology company founded in 2017 by Alec Nielsen, Raja Srinivas, and Christopher Voigt. The company's mission is to apply software engineering principles to cell engineering — treating genetic circuits in mammalian cells the way software engineers treat code. Asimov builds computational tools and AI models that predict how genetic constructs will behave in mammalian cells, enabling researchers to design, simulate, and optimize biologics and gene therapy vectors before conducting expensive wet lab experiments.
Business Model & Competitive Advantage
The company raised a $75M Series B led by Andreessen Horowitz Bio + Health, with additional participation from DCVC Bio, Lux Capital, and others. Asimov's core platform integrates large-scale experimental data generation (using high-throughput DNA synthesis and cell-based assays) with machine learning models that learn the rules governing gene expression, promoter activity, and regulatory element behavior in specific cell types. This creates a virtuous cycle: data informs models, models predict better constructs, experiments validate and refine the models.
Competitive Landscape 2025–2026
Asimov's primary customers are biopharmaceutical companies and CDMOs (contract development and manufacturing organizations) working on recombinant protein biologics and gene therapies. In biologics manufacturing, optimizing expression cassettes in CHO cells (the workhorse of biologic production) is a critical bottleneck — Asimov's tools can accelerate this process from months to weeks. In gene therapy, designing AAV capsids and expression cassettes that achieve therapeutic levels of protein in target tissues is a major technical challenge that Asimov's computational platform directly addresses.
Key Differentiators
Emerging Innovator
Asimov is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
Compare Asimov with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Asimov? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Asimov Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Asimov vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →